Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease
| Autor: | Atsuko Mokubo, Hidetoshi Shimura, Noriko Kaneyama, Hideo Machimura, Shinichi Umezawa, Togo Aoyama, Keiichi Chin, Mitsuo Obana, Akira Kanamori, Masahiro Takihata, Toshimasa Hishiki, Nobuo Hatori, Hiroyuki Sakai, Shinichi Nakajima, Daisuke Suzuki, Tomoya Umezono, Kouta Aoyama, Kazuo Kobayashi, Hisakazu Degawa, Masao Toyoda, Shun Ito, Masaaki Miyakawa, Hareaki Yamamoto, Takayuki Furuki, Hiroshi Takeda |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty Time Factors Article Subject Endocrinology Diabetes and Metabolism Urinary system Urology Blood Pressure Kidney lcsh:Diseases of the endocrine glands. Clinical endocrinology Endocrinology Japan Diabetes mellitus medicine Albuminuria Humans Diabetic Nephropathies Renal Insufficiency Chronic Sodium-Glucose Transporter 2 Inhibitors Aged Retrospective Studies Glycated Hemoglobin lcsh:RC648-665 business.industry Type 2 Diabetes Mellitus Retrospective cohort study Middle Aged medicine.disease Treatment Outcome Blood pressure Mean blood pressure Diabetes Mellitus Type 2 Sodium/Glucose Cotransporter 2 Female business Biomarkers Research Article Kidney disease |
| Zdroj: | Journal of Diabetes Research, Vol 2019 (2019) Journal of Diabetes Research |
| ISSN: | 2314-6753 2314-6745 |
| Popis: | Aim. The renoprotective effect of sodium-glucose cotransporter 2 inhibitors is thought to be due, at least in part, to a decrease in blood pressure. The aim of this study was to determine the renal effects of these inhibitors in low blood pressure patients and the dependence of such effect on blood pressure management status. Methods. The subjects of this retrospective study were 740 patients with type 2 diabetes mellitus and chronic kidney disease who had been managed at the clinical facilities of the Kanagawa Physicians Association. Data on blood pressure management status and urinary albumin-creatinine ratio were analyzed before and after treatment. Results. Changes in the logarithmic value of urinary albumin-creatinine ratio in 327 patients with blood pressure<130/80 mmHg at the initiation of treatment and in 413 patients with BP above 130/80 mmHg were −0.13±1.05 and −0.24±0.97, respectively. However, there was no significant difference between the two groups by analysis of covariance models after adjustment of the logarithmic value of urinary albumin-creatinine ratio at initiation of treatment. Changes in the logarithmic value of urinary albumin-creatinine ratio in patients with mean blood pressure of n=537) and those with ≥102 mmHg (n=203) at the time of the survey were −0.25±1.02 and −0.03±0.97, respectively, and the difference was significant in analysis of covariance models even after adjustment for the logarithmic value of urinary albumin-creatinine ratio at initiation of treatment (p<0.001). Conclusion. Our results confirmed that blood pressure management status after treatment with SGLT2 inhibitors influences the extent of change in urinary albumin-creatinine ratio. Stricter blood pressure management is needed to allow the renoprotective effects of sodium-glucose cotransporter 2 inhibitors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text